Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis.

Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM.

J Clin Invest. 2003 Mar;111(6):821-31.

2.

Osteoclast precursors, RANKL/RANK, and immunology.

Xing L, Schwarz EM, Boyce BF.

Immunol Rev. 2005 Dec;208:19-29. Review.

PMID:
16313338
3.

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.

Kostenuik PJ.

Curr Opin Pharmacol. 2005 Dec;5(6):618-25. Epub 2005 Sep 26. Review.

PMID:
16188502
4.
5.
6.

Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.

Anandarajah AP, Schwarz EM.

J Cell Biochem. 2006 Feb 1;97(2):226-32. Review.

PMID:
16240334
7.
8.

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

Hofbauer LC, Schoppet M.

JAMA. 2004 Jul 28;292(4):490-5. Review.

PMID:
15280347
9.

Bone destruction in arthritis.

Gravallese EM.

Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii84-6. Review.

10.

Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands.

Horowitz MC, Xi Y, Wilson K, Kacena MA.

Cytokine Growth Factor Rev. 2001 Mar;12(1):9-18. Review.

PMID:
11312114
11.

A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.

Takahashi N, Udagawa N, Suda T.

Biochem Biophys Res Commun. 1999 Mar 24;256(3):449-55. Review.

PMID:
10080918
12.

Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.

Tanaka S, Nakamura K, Takahasi N, Suda T.

Immunol Rev. 2005 Dec;208:30-49. Review.

PMID:
16313339
13.

Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.

Kostenuik PJ, Shalhoub V.

Curr Pharm Des. 2001 May;7(8):613-35. Review.

PMID:
11375772
14.

Osteoprotegerin and inflammation.

Saidenberg Kermanac'h N, Bessis N, Cohen-Solal M, De Vernejoul MC, Boissier MC.

Eur Cytokine Netw. 2002 Apr-Jun;13(2):144-53. Review.

15.

Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.

Aubin JE, Bonnelye E.

Osteoporos Int. 2000;11(11):905-13. Review.

PMID:
11193242
16.

Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.

Hofbauer LC, Heufelder AE.

J Mol Med (Berl). 2001 Jun;79(5-6):243-53. Review.

PMID:
11485016
17.

RANK, RANKL and osteoprotegerin in arthritic bone loss.

Bezerra MC, Carvalho JF, Prokopowitsch AS, Pereira RM.

Braz J Med Biol Res. 2005 Feb;38(2):161-70. Epub 2005 Feb 15. Review.

18.

Crystal structure of RANK ligand involved in bone metabolism.

Ito S, Hata T.

Vitam Horm. 2004;67:19-33. Review.

PMID:
15110169
20.

The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption.

Gravallese EM, Galson DL, Goldring SR, Auron PE.

Arthritis Res. 2001;3(1):6-12. Epub 2000 Nov 2. Review.

Supplemental Content

Support Center